Reading KRRO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track KRRO free→Reading KRRO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track KRRO free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been fairly steady, but risk is high, and the sector backdrop is a headwind, with KRRO trading below typical compared to sector peers. Peer multiples imply a price about 28% below where it trades (it looks expensive on this basis); the read is fair, but weakening. The outlook hinges on guidance changes and sector trends, particularly the performance of bellwethers like VRTX, REGN, and ARGX. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $11.66. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $12 KRRO trades at 22× p/s — 2.4× the 9× p/s peer median. The market is re-rating it beyond its own range; our $9.02 fair value is low-confidence here. Analysts: $15–$23. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 29% of near-term growth above a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.62x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates.
9 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-1.82 → $-1.28 (+29.9% / 30d). 3 raised, 2 cut, 9 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 91% of analysts rate Buy.
1 PT revisions / 30d. Avg target 50.5% above current price.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$325.
How much price usually moves either way.
On a bad day, this stock has moved -$798.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $8,972.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
As of June 15, 2026, the valuation dimension changed, moving from expensive to full. The sector backdrop remains a headwind, and risk is high. Recent financial performance is weak, and earnings quality is characterized as loss-making. The management dimension is neutral.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If sector growth improves, it could benefit Korro Bio. A stronger sector can lift all companies within it.
Confirms:Health Care sector revenue growth is speeding up again. This shows a good trend.
Disproves:Sector revenue growth keeps slowing down. This shows ongoing weakness.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for KRRO yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 7, 2026, Korro Bio, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. The full text of the press release is being furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amend…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
$15.00 – $23.00 (median $20.00) · 4 analysts · as of 2026-05-19
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
KRRO Korro Bio, Inc. | Below typical Show detailsSector percentile: 25 of 100 | expensive | high |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 78 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Korro aims to extend its cash runway into the second half of 2028 through strategic financial management.
Stated in 4 of last 4 quarters. Korro's financials show a net income loss of $19.6M in 2026-Q1 and $50.0M in 2025-Q4, with no revenue in 2026-Q1. Despite these losses, management claims the cash runway extends into 2028, supported by strategic financial management and private placements. Persistent statement, limited substantive delivery this quarter.
“Korro expects its cash, cash equivalents and marketable securities as of March 31, 2026 will fund operating expenses and capital expenditure requirements into the second half of 2028.”
“Korro expects its cash, cash equivalents and marketable securities, along with funds from the recent March 2026 private placement financing, to fund operating expenses and capital expenditure require…”
“Korro expects that the net proceeds from the private placement along with its existing cash and equivalents of $85.2 million as of December 31, 2025, will provide runway into the second half of 2028.”
“extending cash runway into second half of 2027 by implementing a strategic restructuring”
Implement strategic restructuring to manage operating expenses and extend cash runway.
Newly stated in 2025-Q2. Korro's financials show operating income losses of $27.2M in 2025-Q2 and $25.0M in 2025-Q1. The strategic restructuring is aimed at managing these expenses to extend the cash runway. Limited progress is evident as operating losses continue.
“extending cash runway into second half of 2027 by implementing a strategic restructuring”
Results of Operations and Financial Condition. On March 12, 2026, Korro Bio, Inc. issued a press release announcing its financial results for the year ended December 31, 2025. The full text of the press release is being furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as am…
Results of Operations and Financial Condition Korro expects to report that it had cash, cash equivalents and marketable securities of approximately $85.2 million as of December 31, 2025. The estimated cash figure is preliminary and unaudited, represents a management estimate as of the date of this current report on Form 8-K and is subject to completion of Korro’s financial closing procedures. Korro’s independent registered public accounting firm has not conducted an audit or review of, and do…
Entry into a Material Definitive Agreement Subscription Agreement On March 9, 2026, Korro Bio, Inc., or Korro, entered into a subscription agreement with a number of institutional accredited investors pursuant to which it agreed to sell and issue in a private placement pursuant to the exemption in Section 4(a)(2) of the Securities Act of 1933, as amended, or the 1933 Act: (i) an aggregate of 4,501,928 shares of its common stock, par value $0.001 per share at a purchase price of $11.11 per sha…
Unregistered Shares of Equity Securities To the extent required by this Item, the information included in